Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension.

ABSTRACT:

Background

Resistant hypertension (rHTN) is defined as blood pressure (BP) of ≥ 140/90 mmHg despite treatment with at least three antihypertensive medications, including a diuretic. Endovascular ultrasound renal denervation (uRDN) aims to control BP alongside conventional BP treatment with antihypertensive medication. This analysis assesses the cost effectiveness of the addition of the Paradise uRDN System compared with standard of care alone in patients with rHTN from the perspective of the United Kingdom (UK) health care system.

Methods

Using RADIANCE-HTN TRIO trial data, we developed a state-transition model. Baseline risk was calculated using Framingham and Prospective Cardiovascular Münster (PROCAM) risk equations to estimate the long-term cardiovascular risks in patien

SUBMITTER: Taylor RS 

PROVIDER: S-EPMC11252101 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature